Anti SARS Spike

Figure 1 Immunofluorescent Validation of 3525 in SARS-CoV-2 Infected Lung Tissue (Singh et al., Nature Microbiology, 2021)
Multilabel confocal immunofluorescence microscopy of formalin-fixed paraffin-embedded lung sections from rhesus macaques infected with SARS-CoV-2. SARS-CoV-2 spike-specific antibodies, 3525 ProSci Inc. (k, n) (turquoise); Ki67 (magenta) and neutrophil marker CD66abce (yellow) (k); pan-macrophage marker CD68 (magenta) (n) and DAPI (blue).

Figure 2 Immunofluorescent Validation of 3525 in SARS-CoV-2 Infected Nose and Tonsil (Singh et al., Nature Microbiology, 2021)
Multi-label confocal immunofluorescence microscopy of nasal epithelium (20X-b, 63xh) and tonsil (20X-c,63X-i) from rhesus macaques infected with SARS-CoV-2 with SARS-CoV-2 spike-specific antibodies, 3525 ProSci Inc. (turquoise), DAPI (blue). Rabbit IgG isotype control antibody wasused to stain the tissues to rule out any non-specific staining (e, f).

Figure 3 Immunofluorescent Validation of 3525 in SARS-CoV-2 Infected Lung Tissue (Singh et al., Nature Microbiology, 2021)
Multilabel confocal immunofluorescence microscopy of formalin-fixed paraffin-embedded lung sections from rhesus macaques infected with SARS-CoV-2. SARS-CoV-2 spike-specific antibodies, 3525 ProSci Inc. (k-s) (turquoise); Ki67 (magenta) and neutrophil marker CD66abce (yellow) (k-m); pan-macrophage marker CD68 (magenta) (n-p); HLA-DR (magenta) and pDC marker CD123 (yellow) (q？s) and DAPI (blue).

Figure 4 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Spike in COVID-19 Patient Lung
Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti-SARS-CoV-2 (COVID-19) Spike S2 antibody (3525, 0.5 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 ℃. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong spike protein signal was observed in macrophages and airway epithelium of COVID-19 patient lung, but not in non-COVID-19 patient lung.

Figure 5 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Spike in COVID-19 Patient Lung
Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti-SARS-CoV-2 (COVID-19) Spike S2 antibody (3525, 0.5 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 ℃. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.Strong spike protein signal was observed in macrophages of COVID-19 patient lung.

Figure 6 IHC/IF Validation in COVID-19 Patient Sample
(Nuovo et al., 2020)Detection of SARS-CoV-2 proteins in nasopharyngeal swab cell preparations. B. An intense signal for covid-19 spike protein tested by SARS-CoV-2 spike antibodies (3525) was observed in the glandular cells. F-H. Co-expression of spike detected by spike antibodies (3525, 0.2 μg/mL) and envelope proteins detected by envelope antibodies (3531, 2 μg/mL) of SARS-CoV-2 (F) documented localization of each protein to glandular cells (G, yellow). No signal was seen in oral swabs of positive cases (H). Both the spike and envelope protein detected by anti-spike antibodies (3525) and anti-envelope antibodies (3531) produced a signal in the nasopharyngeal swabs of the three cases and no signal was evident in the nasopharyngeal swabs of the seven controls.

Figure 7 IF Validation of SARS-CoV2 Spike in COVID-19 Patient Lung
(Magro et al., 2020) SARS-CoV2 spike protein (red, panel C) detected detected by anti-spike antibodies (3525, 0.2 μg/mL) colocalized with C4d (green in panel d, merged in yellow). Spike protein (red, panel g) was also colocalized with C5b-9 (green in panel f&h, merged in yellow)

Figure 8 IF Validation of SARS-CoV2 Spike in COVID-19 Patient Skin
(Magro et al., 2020) C4d is highlighted green while COVID-19 spike protein detected by anti-spike antibodies (3525, 0.2 μg/mL) shows a red staining pattern; a yellow signal is discernible indicative of co-localization of C4d and viral protein within the microvasculature.

Figure 9 IHC Validation of SARS-CoV2 Spike in the Nasopharyngeal Swab Sample of the COVID-19 Patient
Strong spike signal was detected by anti-spike antibodies (3525, 0.2 μg/mL) in the nasopharyngeal swab sample of the COVID-19 patient and no spike signal was observed in the sample of the COVID-19 negative patient. COVID-19 cases were confirmed by PCR. (Courtesy of Dr. Nuovo Gerard J., OSU)

Figure 10 IHC Validation of SARS-CoV2 Spike in COVID-19 Patient Lung
Strong spike signal was detected by anti-spike antibodies (3525, 0.2 μg/mL) in the lung of the COVID-19 patient confirmed by PCR. (Courtesy of Dr. Nuovo Gerard J., OSU)